GlassScriptPhysician profile
Hakumat R Kakkar
NPI 1205896651
$7,708.05
in general payments reported to CMS, 2019-2025
37 companies · $629 in 2025
The $629 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $1,198 · 2021: $1,613 · 2022: $900 · 2023: $1,668 · 2024: $479 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018 · Travel and Lodging: $741 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.32 |
| Travel and Lodging | $741.17 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,337.72 | 2019-2025 | Infinity |
| Novartis Pharmaceuticals Corporation | $999.99 | 2019-2025 | |
| Livanova USA, INC. | $749.03 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Emd Serono, INC. | $442.62 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $430.79 | 2020-2021 | |
| Merz North America, INC. | $293.58 | 2019-2023 | Xeomin |
| Allergan, INC. | $241.13 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $218.81 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $161.80 | 2019-2022 | |
| Ucb, INC. | $159.62 | 2023-2025 | Fintepla, Briviact |
| Biogen, INC. | $154.96 | 2019-2021 | |
| Lilly USA, LLC | $151.56 | 2020-2025 | Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $128.48 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $127.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $115.13 | 2020-2023 | Ultomiris |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $101.17 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $98.27 | 2020-2022 | |
| Kyowa Kirin, INC. | $90.01 | 2019-2021 | |
| Genentech USA, INC. | $84.19 | 2021-2023 | Ocrevus |
| Eisai INC. | $82.32 | 2020-2022 | |
| Argenx US, INC. | $61.92 | 2022-2023 | Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $60.65 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $43.55 | 2020-2022 | |
| Genzyme Corporation | $41.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $39.84 | 2020-2021 | |
| Sk Life Science, INC. | $39.19 | 2021 | |
| Lundbeck LLC | $38.18 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $33.85 | 2021-2024 | |
| Abbvie INC. | $32.10 | 2021-2022 | |
| Cvrx, INC. | $25.06 | 2025 | Barostim Neo System |
| Acorda Therapeutics, INC | $21.85 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.24 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.84 | 2024 | Rexulti |
| Alnylam Pharmaceuticals INC. | $17.62 | 2023 | Onpattro |
| Avion Pharmaceuticals | $15.63 | 2023 | Dhivy |
| Biotronik INC. | $14.61 | 2020 | |
| Banner Life Sciences, LLC | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hakumat Kakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.